Janney Montgomery Scott LLC grew its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 0.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 363,777 shares of the pharmaceutical company’s stock after acquiring an additional 2,835 shares during the quarter. Janney Montgomery Scott LLC’s holdings in GlaxoSmithKline were worth $14,613,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in GSK. Optimum Investment Advisors lifted its position in shares of GlaxoSmithKline by 88.5% during the 3rd quarter. Optimum Investment Advisors now owns 2,749 shares of the pharmaceutical company’s stock valued at $110,000 after acquiring an additional 1,291 shares during the period. Kiley Juergens Wealth Management LLC bought a new stake in shares of GlaxoSmithKline during the 2nd quarter valued at $113,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of GlaxoSmithKline during the 2nd quarter valued at $134,000. Toronto Dominion Bank lifted its position in shares of GlaxoSmithKline by 46.0% during the 2nd quarter. Toronto Dominion Bank now owns 4,600 shares of the pharmaceutical company’s stock valued at $186,000 after acquiring an additional 1,450 shares during the period. Finally, Amussen Hunsaker Associates LLC bought a new stake in shares of GlaxoSmithKline during the 2nd quarter valued at $193,000. Hedge funds and other institutional investors own 11.01% of the company’s stock.
GlaxoSmithKline stock opened at $41.30 on Friday. The company has a quick ratio of 0.63, a current ratio of 0.95 and a debt-to-equity ratio of 6.66. GlaxoSmithKline plc has a 52 week low of $34.52 and a 52 week high of $42.36. The firm has a market cap of $101.21 billion, a PE ratio of 13.60, a price-to-earnings-growth ratio of 2.74 and a beta of 0.80.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 10th. Stockholders of record on Friday, November 16th will be issued a dividend of $0.486 per share. The ex-dividend date of this dividend is Thursday, November 15th. This represents a $1.94 dividend on an annualized basis and a dividend yield of 4.71%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.46. GlaxoSmithKline’s payout ratio is 68.06%.
A number of research firms have recently commented on GSK. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Tuesday, September 25th. Goldman Sachs Group reissued a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday, October 10th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, September 25th. Guggenheim began coverage on GlaxoSmithKline in a report on Monday, October 8th. They set a “neutral” rating for the company. Finally, ValuEngine raised GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Friday, October 19th. Eleven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $41.57.
WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/11/10/glaxosmithkline-plc-gsk-stake-increased-by-janney-montgomery-scott-llc.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Discount Rate
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.